Clinical trial
Vaccine Therapy in Treating Patients With High-Risk Stage III or Completely…
NCT00019890 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00019890 |
|---|---|
| Title | Vaccine Therapy in Treating Patients With High-Risk Stage III or Completely Resected Metastatic Melanoma |
| Official title | Phase II Randomized Study of CD34+ Derived or Peripheral Monocyte Derived Dendritic Cells Pulsed With MART-1 and gp100 Melanoma Antigens in Patients With High Risk Stage III or Completely Resected Metastatic Melanoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Stage IV Melanoma, Stage III Melanoma, Recurrent Melanoma |
| Intervention type | Drug |
| Interventions | dendritic cell-gp100-MART-1 antigen vaccine, sargramostim |
| Completion | Mar 1, 2007 |
| First posted | Mar 5, 2007 |
| Last update posted | Mar 4, 2024 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: